Who are Vaginal conjugated estrogen cream 0.5gm's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Premarin, Premarin, Premarin, Estradiol patch, Postmenopausal, topical vaginal estrogen cream, Estring Vaginal Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vaginal-conjugated-estrogen-cream-0-5gm.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Vaginal conjugated estrogen cream 0.5gm — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vaginal conjugated estrogen cream 0.5gm (Vaginal conjugated estrogen cream 0.5gm) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: estrogen replacement therapy. Area: Women's Health.

phase 3 estrogen replacement therapy Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

Vaginal conjugated estrogen cream 0.5gm (Vaginal conjugated estrogen cream 0.5gm) — TriHealth Inc.. Estrogen replacement therapy to alleviate menopausal symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vaginal conjugated estrogen cream 0.5gm TARGET	Vaginal conjugated estrogen cream 0.5gm	TriHealth Inc.	phase 3	estrogen replacement therapy
Premarin	Estrogens, Conjugated	Pfizer	marketed	Estrogen replacement therapy	Estrogen receptors (nuclear receptors)	1942-01-01
Premarin	Estrogens, Conjugated	Pfizer	marketed	Estrogen replacement therapy	Estrogen receptors (nuclear receptors)	1942-01-01
Premarin	Estrogens, Conjugated	Pfizer	marketed	Estrogen replacement therapy	Estrogen receptors (nuclear receptors)	1942-01-01
Estradiol patch	Estradiol patch	University of Virginia	marketed	Estrogen replacement therapy	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Postmenopausal, topical vaginal estrogen cream	Postmenopausal, topical vaginal estrogen cream	The University of Texas Medical Branch, Galveston	marketed	Estrogen replacement therapy (topical)	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Estring Vaginal Product	Estring Vaginal Product	University of California, Irvine	marketed	Estrogen replacement therapy (vaginal)	Estrogen receptor (ER-α and ER-β)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (estrogen replacement therapy class)

TriHealth Inc. · 2 drugs in this class
Queen's University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vaginal conjugated estrogen cream 0.5gm — Competitive Intelligence Brief. https://druglandscape.com/ci/vaginal-conjugated-estrogen-cream-0-5gm. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab